BRIEF-Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

Vertex Pharmaceuticals Incorporated -0.46%

Vertex Pharmaceuticals Incorporated

VRTX

439.18

-0.46%

March 9 (Reuters) - Vertex Pharmaceuticals Inc VRTX.O:

  • VERTEX ANNOUNCES POSITIVE WEEK 36 INTERIM ANALYSIS RESULTS FOR PRIMARY AND ALL SECONDARY ENDPOINTS IN THE RAINIER PHASE 3 TRIAL OF POVETACICEPT IN ADULTS WITH IGA NEPHROPATHY

  • VERTEX PHARMACEUTICALS INC - TO COMPLETE BLA FOR POVETACICEPT BY END OF MARCH FOR POTENTIAL U.S. ACCELERATED APPROVAL

  • VERTEX PHARMACEUTICALS: POVETACICEPT WAS GENERALLY SAFE AND WELL TOLERATED

Source text: ID:nBw2NCH39a

Further company coverage: VRTX.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.